1.
Clin Rheumatol
; 33(8): 1183-4, 2014 Aug.
Article
in English
| MEDLINE
| ID: mdl-24478126
ABSTRACT
Takayasu arteritis (TA) is a rare form of chronic large vessel vasculitis of unknown origin involving the aorta and its major branches. Recently, the involvement of B lymphocytes in TA has been suggested, and active refractory TA patients were successfully treated with B cell depletion therapy (BCDT). We report two cases of patients with TA successfully treated with anti-CD20 monoclonal antibody (rituximab). The favorable outcome of rituximab treatment in our patients also support the view that BCDT can be a useful option for refractory TA, and its potential should be evaluated in controlled trials.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Immunologic Factors/therapeutic use , Takayasu Arteritis/drug therapy , Adult , Female , Humans , Rituximab , Treatment Outcome
2.
Scand J Rheumatol
; 41(5): 403-5, 2012 Oct.
Article
in English
| MEDLINE
| ID: mdl-23043346